Paper Alert: Astrocyte Receptor Could Hinder Memory
People with Alzheimer’s overexpress the A2A receptor, which suppresses memory in mice.
6397 RESULTS
Sort By:
People with Alzheimer’s overexpress the A2A receptor, which suppresses memory in mice.
Hollywood turns its attention to a rare form of dementia, giving a personal look at the impact of the disease.
All three PET agents demonstrate roughly equivalent abilities to detect brain amyloid, a new analysis finds.
Upper motor neurons, implicated in many neurodegenerative diseases, are sensitive to both cell stress and hyperexcitability.
Spinal taps have a bad rap. Are headaches really all that common afterwards, and are there ways to prevent them?
The classic kinase cascade conspires to commit programmed axonal degeneration after injury.
For the first time, scientists report a crystal structure of TSPO, a potential target for PET imaging of neuroinflammation.
Scientists have produced an atomic-level picture of a receptor implicated in both the sporadic and familial forms of Alzheimer’s.
The field of tau PET is growing rapidly as the leading tracer T807/AV1451 is more widely used and new compounds from Japan and Switzerland enter the scene with clinical trials of their own.
Human Amyloid Imaging Meeting Was Abuzz With Talk of Tau Tau Tracer T807/AV1451 Tracks Neurodegenerative Progression Tau PET Fits With CSF, Grows Over Time, Picks up Frontotemporal Cases What If It’s Not Garden-Variety AD? Telling Variants Apart by Where
Loss of the microRNA leads to glutamate toxicity and neurodegeneration.
Data come tumbling in as more people are getting scans with the first widely used tau PET tracer. Scientists at HAI were pleased by how closely degeneration and symptoms match up in Alzheimer’s.
Early data suggest that the T807/AV1451 signal relates to cerebrospinal biomarkers of Alzheimer’s, intensifies by up to 10 percent a year, and might nail diagnoses beyond typical AD.
Autoradiography confirms that T807/AV1451 binds tau but not TDP-43. Even so, some say the tracer will benefit from more technical work to ensure it will measure small changes robustly in multicenter settings.
Keystone Symposia Meeting, Part 1—Alzheimer’s Disease: Genes, Cellular Pathways and Therapies Keystone Symposia Meeting, Part 2—Genetics and Epidemiology of AD Keystone Symposia Meeting, Part 3—Amyloid Precursor Protein Function Keystone Symposia Meeting,